Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)

Inclusion Criteria:

- Women aged 18 and above;

- Have high grade squamous intraepithelial lesion (HSIL) of the vulva (VIN2 or VIN3)
caused by infection with HPV types 16 and/or 18 confirmed at screening visit;

Exclusion Criteria:

- Biopsy-proven differentiated VIN;

- Any previous treatment for vulvar HSIL within 4 weeks prior to screening;

- Allergy to imiquimod 5% cream or to an inactive ingredient in imiquimod 5% cream;

- Pregnant, breastfeeding or considering becoming pregnant within 6 months following the
last dose of investigational product;

- Immunosuppression as a result of underlying illness or treatment;

- Significant acute or chronic medical illness.